Related Experiment Video
Updated: Jul 16, 2025
07:39
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
170
c-Myc inhibits LAPTM5 expression in B-cell lymphomas
Yanqing Zhang1,2, Xin Zhang1,2,3, Yi Zhang1,2
1Institute of Translational Medicine, Yangzhou University Medical College, Yangzhou, China.
Annals of Hematology
|September 15, 2023
Summary
Myc, a key factor in B-cell lymphomas, represses LAPTM5 expression. This repression, along with increased miR-17-3p, promotes tumor growth by inhibiting tumor-suppressive LAPTM5 protein.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Myc is a protooncogene crucial in B-cell lymphomas.
- Mechanisms of Myc-driven B-cell proliferation are not fully understood.
Purpose of the Study:
- To elucidate how Myc contributes to B-cell lymphoma progression.
- To investigate the role of LAPTM5 and miR-17-3p in Myc-mediated B-cell proliferation.
Main Methods:
- Investigated Myc's regulation of LAPTM5 expression via promoter binding.
- Assessed the impact of LAPTM5 mRNA variants (CDS, 3'UTR) on B-lymphoma growth.
- Analyzed Myc's transactivation of miR-17-3p and its binding to LAPTM5 3'UTR.
Main Results:
- Myc represses murine LAPTM5 gene expression by binding to its promoter.
- LAPTM5 CDS or 3'UTR, but not intact mRNA, inhibits B-lymphoma growth.
- Myc upregulates miR-17-3p, which binds to LAPTM5 3'UTR, inhibiting protein synthesis.
- Combined transcriptional and post-transcriptional repression of LAPTM5 by Myc promotes lymphoma progression.
Conclusions:
- Myc inhibits LAPTM5 expression through both transcriptional and post-transcriptional mechanisms.
- The interplay between reduced LAPTM5 and elevated miR-17-3p, driven by Myc, facilitates B-cell lymphoma progression.
Related Concept Videos
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:06Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
01:31The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K